Arlington, MA, United States of America

Mark N Namchuk

This inventor holds 3 USPTO granted patents, plus 1 CIPO patent. Top assignees: Alkermes, Inc., Vertex Pharmaceuticals, Inc.. Active years: 2006-2022.


% Patents Active = 66.7


Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2006-2022

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Mark N Namchuk: Innovator in Immunology

Introduction

Mark N Namchuk is a prominent inventor based in Arlington, MA (US). He has made significant contributions to the field of immunology, particularly through his innovative work on IL-10 polypeptides. With a total of 3 patents to his name, Namchuk's inventions focus on modulating immunostimulatory and anti-inflammatory properties.

Latest Patents

Namchuk's latest patents include compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties. The invention provides scIL-10 polypeptides that can be linked to a fusion partner. These polypeptides are designed to enhance the immunostimulatory properties of IL-10, which is crucial for developing therapeutic strategies in immunology.

Career Highlights

Throughout his career, Mark N Namchuk has worked with notable companies such as Alkermes, Inc. and Vertex Pharmaceuticals, Inc. His experience in these organizations has allowed him to refine his expertise in the development of innovative immunological therapies.

Collaborations

Namchuk has collaborated with esteemed colleagues, including Demetri Theodore Moustakas and Heather C Losey. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Mark N Namchuk stands out as a key figure in the field of immunology, with his innovative patents paving the way for future advancements in therapeutic applications. His work continues to influence the scientific community and improve health outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…